Congestive Heart Failure Clinical Trial
Official title:
Paceport Swan-Ganz Data Collection Study
NCT number | NCT04782154 |
Other study ID # | 2018-20 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 9, 2021 |
Est. completion date | April 1, 2022 |
Verified date | August 2022 |
Source | Montreal Heart Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
RV dysfunction has been associated with increased mortality in the ICU and cardiac surgical patients. Thus, early identification of RV dysfunction at less severe stages will allow for earlier intervention and potentially better patient outcomes. However, so far, no studies have reported prospectively the prevalence of abnormal RV pressure waveform during cardiac surgery and in the ICU. Our primary hypothesis is that the prevalence of abnormal RV pressure waveform occurs in more than 50% of cardiac surgical patients throughout their hospitalization. Those patients with abnormal RV pressure waveform will be more prone to post-operative complications related to RV dysfunction and failure in the OR and ICU.
Status | Completed |
Enrollment | 136 |
Est. completion date | April 1, 2022 |
Est. primary completion date | March 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be = 18 years of age - Participate in the Informed Consent process and sign/date the approved informed consent forms - Projected to receive Swan-Ganz catheter as part of procedure/standard of care with intermittent cardiac output and mixed venous oxygen saturation (SvO2) measures Exclusion Criteria: - Refuse to sign consent - Have left bundle branch block - Have recurrent sepsis - Have hypercoagulopathy - Allergic to FORE-SIGHT Elite sensor adhesive - Latex allergy due to presence of latex in the Swan-Ganz catheter balloon. |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal Heart Institute | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Montreal Heart Institute | Edwards Lifesciences |
Canada,
Amsallem M, Kuznetsova T, Hanneman K, Denault A, Haddad F. Right heart imaging in patients with heart failure: a tale of two ventricles. Curr Opin Cardiol. 2016 Sep;31(5):469-82. doi: 10.1097/HCO.0000000000000315. Review. — View Citation
Denault A, Lamarche Y, Rochon A, Cogan J, Liszkowski M, Lebon JS, Ayoub C, Taillefer J, Blain R, Viens C, Couture P, Deschamps A. Innovative approaches in the perioperative care of the cardiac surgical patient in the operating room and intensive care unit. Can J Cardiol. 2014 Dec;30(12 Suppl):S459-77. doi: 10.1016/j.cjca.2014.09.029. Epub 2014 Oct 5. Review. — View Citation
Denault AY, Bussières JS, Arellano R, Finegan B, Gavra P, Haddad F, Nguyen AQ, Varin F, Fortier A, Levesque S, Shi Y, Elmi-Sarabi M, Tardif JC, Perrault LP, Lambert J. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anaesth. 2016 Oct;63(10):1140-53. doi: 10.1007/s12630-016-0709-8. Epub 2016 Jul 28. — View Citation
Denault AY, Chaput M, Couture P, Hébert Y, Haddad F, Tardif JC. Dynamic right ventricular outflow tract obstruction in cardiac surgery. J Thorac Cardiovasc Surg. 2006 Jul;132(1):43-9. — View Citation
Denault AY, Couture P, Buithieu J, Haddad F, Carrier M, Babin D, Levesque S, Tardif JC. Left and right ventricular diastolic dysfunction as predictors of difficult separation from cardiopulmonary bypass. Can J Anaesth. 2006 Oct;53(10):1020-9. — View Citation
Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: II. Pathophysiology, clinical importance, and management. Anesth Analg. 2009 Feb;108(2):422-33. doi: 10.1213/ane.0b013e31818d8b92. Review. — View Citation
Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008 Mar 18;117(11):1436-48. doi: 10.1161/CIRCULATIONAHA.107.653576. Review. — View Citation
Hrymak C, Strumpher J, Jacobsohn E. Acute Right Ventricle Failure in the Intensive Care Unit: Assessment and Management. Can J Cardiol. 2017 Jan;33(1):61-71. doi: 10.1016/j.cjca.2016.10.030. Epub 2016 Nov 11. Review. — View Citation
Mehta Y, Arora D. Newer methods of cardiac output monitoring. World J Cardiol. 2014 Sep 26;6(9):1022-9. doi: 10.4330/wjc.v6.i9.1022. Review. — View Citation
Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014 Dec;23(134):476-87. doi: 10.1183/09059180.00007414. Review. — View Citation
Raymond M, Grønlykke L, Couture EJ, Desjardins G, Cogan J, Cloutier J, Lamarche Y, L'Allier PL, Ravn HB, Couture P, Deschamps A, Chamberland ME, Ayoub C, Lebon JS, Julien M, Taillefer J, Rochon A, Denault AY. Perioperative Right Ventricular Pressure Monitoring in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Apr;33(4):1090-1104. doi: 10.1053/j.jvca.2018.08.198. Epub 2018 Aug 25. Review. — View Citation
Richard C, Monnet X, Teboul JL. Pulmonary artery catheter monitoring in 2011. Curr Opin Crit Care. 2011 Jun;17(3):296-302. doi: 10.1097/MCC.0b013e3283466b85. Review. — View Citation
Rubenfeld GD, Angus DC, Pinsky MR, Curtis JR, Connors AF Jr, Bernard GR. Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research. The Members of the Outcomes Research Workshop. Am J Respir Crit Care Med. 1999 Jul;160(1):358-67. — View Citation
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. — View Citation
St-Pierre P, Deschamps A, Cartier R, Basmadjian AJ, Denault AY. Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma. J Cardiothorac Vasc Anesth. 2014 Jun;28(3):723-9. doi: 10.1053/j.jvca.2012.10.017. Epub 2013 Apr 26. — View Citation
Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med. 1970 Aug 27;283(9):447-51. — View Citation
* Note: There are 16 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of abnormal diastolic RV waveforms before CPB, after CPB and in the ICU | Abnormal RV pressure waveform will be defined as a difference between the RV end-diastolic minus the early-diastolic pressure > 4 mmHg and a RVdP/dt < 400 mmHg. | From thermodilution catheter insertion until 2 hours after ICU arrival | |
Secondary | Proportion of patients with difficult and complex separation from cardiopulmonary bypass at the end of cardiac surgery | Difficult separation from cardiopulmonary bypass: instability requiring at least two different types of pharmacological agents (i.e., inotropes ± vasopressors ± inhaled agents) Complex separation from cardiopulmonary bypass: Hemodynamic instability requiring return on cardiopulmonary bypass or addition of mechanical support (intra-aortic balloon pump or extra-corporeal membrane oxygenator) | From the discontinuation of cardiopulmonary bypass until ICU arrival after surgery, assessed up to 4 hours | |
Secondary | Cumulative time of Persistent Organ Dysfunction or Death (TPOD) during the first 28 days after cardiac surgery | TPOD is a continuous variable representative of the burden of care and morbidity during the first 28 days following cardiac surgery and was chosen to circumvent issues arising for using other clinical endpoint such as ICU length of stay | Up to 28 days or until hospital discharge | |
Secondary | Incidence of deaths during hospitalisation | Death from any cause | Up to 28 days or until hospital discharge | |
Secondary | Incidence of acute kidney injury (AKI) | Acute kidney injury (AKI) according to KDIGO serum creatinine criteria: Stage 1: =50% or 27 umol/L increases in serum creatinine, Stage 2: =100% increase in serum creatinine, Stage 3 =200% increase in serum creatinine or an increase to a level of =254 umol/L or dialysis initiation. | Up to 28 days or until hospital discharge | |
Secondary | Incidence of major bleeding | Major bleeding is defined by the Bleeding Academic Research Consortium (BARC) as one of the following: • Perioperative intracranial bleeding within 48h • Reoperation after closure of sternotomy for the purpose of controlling bleeding • Transfusion of =5 units of whole blood of packed red blood cells within a 48 hours period • Chest tube output =2L within a 24 hours period | Up to 28 days or until hospital discharge | |
Secondary | Incidence of surgical reintervention for any reasons | Re-operation after the initial surgery for any cause | Up to 28 days or until hospital discharge | |
Secondary | Incidence of deep sternal wound infection or mediastinitis | Diagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician | Up to 28 days or until hospital discharge | |
Secondary | Incidence of delirium | Delirium is defined as an intensive care delirium screening checklist (ICDSC) score(18) of =4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU). | Up to 28 days or until hospital discharge | |
Secondary | Incidence of stroke | Central neurologic deficit persisting longer than 72 hours | Up to 28 days or until hospital discharge | |
Secondary | Total duration of ICU stay in hours | Number of hours passed in the ICU | Up to 28 days or until hospital discharg | |
Secondary | Duration of vasopressor requirements (in hours) | Vasopressors include norepinephrine, epinephrine, dobutamine, vasopressin, phenylephrine, milrinone, isoproterenol and dopamine | Up to 28 days or until hospital discharge | |
Secondary | Up to 28 days or until hospital discharge | Number of days hospitalized from the day of surgery to discharge | Up to 28 days or until hospital discharge | |
Secondary | Duration of mechanical ventilation (in hours) | A duration of >24 hours will be considered prolonged ventilation requirements. | Up to 28 days or until hospital discharge | |
Secondary | Incidence of major morbidity or mortality | Including death, prolonged ventilation, stroke, renal failure (Stage =2), deep sternal wound infection and reoperation for any reason. | Up to 28 days or until hospital discharge | |
Secondary | Right ventricular ejection fraction | Assessed by the American Society of Echocardiography guidelines | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular fractional area change | Assessed by the American Society of Echocardiography guidelines | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular strain | Assessed by the American Society of Echocardiography guidelines | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Tricuspid annular plane systolic excursion | Assessed by the American Society of Echocardiography guidelines | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular performance index | Assessed by the American Society of Echocardiography guidelines | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Portal flow pulsatility fraction | Portal flow pulsatility fraction | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular stroke work index | 0.0136x Stroke volume index x (Mean pulmonary artery pressure-mean right atrial pressure) | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Relative pulmonary pressure | The ratio of the mean systemic arterial pressure divided by the mean pulmonary artery pressure | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular function index | Defined as (isovolumic contraction time + isovolumic relaxation time)/RV ejection time | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Pulmonary artery pulsatility index (PAPi) | Defined as (systolic pulmonary artery pressure - diastolic pulmonary artery pressure)/central venous pressure | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Compliance of the pulmonary artery (CPA) | Stroke volume divided by the pulmonary artery pulse pressure (systolic minus the diastolic pulmonary artery pressure) | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Pulsatility of femoral venous flow | Velocity variations of blood flow in the femoral vein during the cardiac cycle | From arrival to the operating room until 2 hours after ICU arrival | |
Secondary | Right ventricular outflow tract obstruction | Right Ventricular Systolic pressure minus Pulmonary Artery Systolic pressure = 6 mmHg. | From arrival to the operating room until 2 hours after ICU arrival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Recruiting |
NCT04703842 -
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
|
Phase 1/Phase 2 | |
Terminated |
NCT05594940 -
Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
|
||
Recruiting |
NCT04982081 -
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
|
Phase 1 | |
Completed |
NCT04394754 -
Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure
|
N/A | |
Active, not recruiting |
NCT01385176 -
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
|
N/A | |
Not yet recruiting |
NCT05516290 -
Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
|
||
Completed |
NCT02885636 -
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
|
Phase 3 | |
Terminated |
NCT02788656 -
Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
|
Phase 4 | |
Completed |
NCT02252757 -
Assess Measurements of Wireless Cardiac Output Device
|
N/A | |
Terminated |
NCT02205411 -
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Withdrawn |
NCT00346177 -
Stem Cell Study for Patients With Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT01058837 -
SCD-HeFT 10 Year Follow-up
|
N/A | |
Completed |
NCT00957541 -
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
|
Phase 2 |